proSpecTive sAmpling in dRiver muTation pulmonary oncology patients on Tyrosine Kinase Inhibitors

Recruiting

• Conditions: lung cancer; non-small cell lung cancer; 10029107

• Registration Number: NL-OMON55730
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 1300

Inclusion Criteria

• Age >= 18 years
• Able to understand the written informed and able to give informed consent
• Locally advanced or metastatic lung cancer with oncogenic driver mutation
• Treatment with TKI according to standard of care

Exclusion Criteria

• Unable to draw blood for study purposes

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>(Resistance) mutation plasma levels, pharmacokinetics of TKI (through levels)<br /><br>during treatment and at progression.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Primary mutation levels, time to progression, correlation to (re)biopsy<br /><br>specimen results performed for standard-of-care. Furthermore TKI, smoking<br /><br>status, BMI.</p><br>